UPDATED: Kite Pharma soars on added evidence that CAR-T treatment quells cancer

John Carroll Kite Pharma has once again demonstrated just how hot experimental CAR-T technology is in the cancer field. The Santa Monica, CA-based biotech reported Monday evening in ...

Big Pharma to share abandoned drugs, Actelion M&A rumors resume, Gaza war threatens IPOs

Nick Paul Taylor In this week's EuroBiotech Report, events in Gaza and Ukraine have cast a shadow over Europe, with sections of the Israeli biotech industry among the many groups ...

Pharma peer pressure makes tax-friendly M&A targets the new must-have

Tracy Staton Talk about peer pressure. First, a couple of U.S. drugmakers pull off trans-Atlantic deals that shift their official HQs and lower their tax rates. Next, some bigger names ...

When will Big Pharma get serious about antibiotic R&D?

Damian Garde The 5 most promising antibiotic treatments in the industry's pipeline all have something in common: Not one was developed by Big Pharma. FierceBiotech News

Belgium’s Omega Pharma may be the next seller in OTC deal wave

Carly Helfand Lately, OTC businesses have been selling like hotcakes, with a number of global consumer players looking to bulk up. Now, reports say Belgium's Omega Pharma could ...

Baxter gets C-suite lined up ahead of pharma spinoff

Carly Helfand Baxter has tapped a couple of new execs for the biopharma unit it plans to spin off next year. And with new competition in one of the division's bigger markets, its ...

Study: Med students cozy with pharma reps more likely to dole out branded drugs

Emily Wasserman Doctors aren't the only ones to fall prey to free lunches and fuzzy promotional talks. Medical students who spend more time with& pharma reps are more likely ...

Merck KGaA takes the long view on troubled pharma biz

Damian Garde A series of setbacks has made things tough for Merck KGaA's drug development operation, but CEO Karl-Ludwig Kley said the German company remains committed to the long-term ...

Par Pharma nabs injectables specialist JHP for $490M in private-equity auction

Tracy Staton Generics maker Par Pharmaceutical inked a deal to pay $ 490 million for JHP Pharmaceuticals, a specialty pharma company owned by Warburg Pincus. Par will gain a portfolio ...

Indian drugmakers grab big share of U.K. pharma market

Tracy Staton In the U.K., drugs produced in India are almost as common as those made in Britain, a new report from the Medicines and Healthcare Products Regulatory Agency says. FiercePharma ...

Giving letter grades for 2013 pharma performance

Eric Palmer Anyone can judge drugmakers' annual results by the numbers: top line, bottom line, growth, earnings or some combination of financial markers. It's more daring to ...

Chinese whistleblower tags Shanghai Pharma with bribery allegations

Tracy Staton Shanghai Pharma, one of China's largest drugmakers, said it is investigating whistleblower claims that it bribed hospital staffers to amp up sales of its drugs. According ...
Page 5 of 17« First...34567...10...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS